Galan is set to begin the scoping study for its Candelas project in the South American lithium triangle in Catamarca, Argentina. 

The project’s brine concentrate modelling shows results of up to 6%Li – similar to that of the company’s Hombre Muerto West (HWM) project concentrate with low impurities.

Galan (ASX:GLN) will build from the learnings at HMW’s PEA Study (released 21 Dec 2020) with an in-house team and Ad-Infinitum overseeing the chemical processing and other relevant study sections.

Results are expected during Q4 2021.

Data backs scoping study

To date geophysics and drilling have indicated Candelas has the potential to host a substantial volume of brine and over which a maiden resource estimated 685,000 tonnes LCE (Oct 2019).

Plus, the project also has the potential to provide a substantial amount of processing water by treating its low-grade brines with reverse osmosis – without using surface water from Los Patos River.

“We are very pleased with Candelas’ modelling results for its lithium chloride concentrate,” Galan managing director Juan Pablo (JP) Vargas de la Vega said.

“Results are showing that it can reach up to 6%Li with a low impurity setting which can provide commercial flexibility to production.

“To date, we have accumulated a significant amount of data from our detailed studies and testing at HMW which gives us the confidence to take Candelas into the scoping study phase.”

Potential to increase production

“This next step is a natural step to complement our lithium inventory from the same salt flat with an aim to add further value by investigating an increase in production levels for Galan,” Vargas de la Vega said.

The company will also continue feasibility study activities at HMW alongside the Candelas scoping study.

 

 

 

This article was developed in collaboration with Galan Lithium, a Stockhead advertiser at the time of publishing.

 

This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.